Transactions
2
Insider / BIOCRYST PHARMACEUTICALS INC
Ghias Babar
Chief Financial Officer at BIOCRYST PHARMACEUTICALS INC
- Company
- BIOCRYST PHARMACEUTICALS INC
- Ticker
- BCRX
- First filing on record
- December 19, 2025
- Latest trade on record
- December 17, 2025
- SEC filings
- EDGAR ↗
Ghias Babar, Chief Financial Officer at BIOCRYST PHARMACEUTICALS INC, has disclosed 2 transactions in BCRX since December 19, 2025: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed December 19, 2025, 2 days after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
2.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Ghias Babar reported 2 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 476,750 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2025 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BCRX | Other A | December 17, 2025 | December 19, 2025 | 2d | 355,050 | — | — | derivative | Form 4 ↗ | |
| BCRX | Other A | December 17, 2025 | December 19, 2025 | 2d | 121,700 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| December 19, 2025 | Form 4 | 0000882796-25-000038 | 2 | published | EDGAR ↗ |
Other insiders at BIOCRYST PHARMACEUTICALS INC
- Barnes Alane P Chief Legal Officer 17 rows
- Stonehouse Jon P Director 13 rows
- Gayer Charles K President and CCO 10 rows
- Milne Jill C. Director 8 rows
- McKee Amy E Director 7 rows
- Frank Steven Director 6 rows
- MILANO VINCENT Director 6 rows
- HEGGIE THERESA Director 5 rows
- SANDERS MACHELLE Director 3 rows
- Galson Steven K Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: BIOCRYST PHARMACEUTICALS INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 2 | December 19, 2025 | December 19, 2025 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.